Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials

References

• SabattiniEBacciFSagramosoCPileriSAWHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overviewPathologica20101023838721171509
   PubMedGoogle Scholar
• BroijlASonneveldPAn update in treatment options for multiple myeloma in nontransplant eligible patientsExpert Opin Pharmacother201516131945195726245702
   PubMed Web of Science ®Google Scholar
• CottiniFAndersonKNovel therapeutic targets in multiple myelomaClin Adv Hematol Oncol201513423624826352582
   PubMedGoogle Scholar
• LiuXHeCKMengXBortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trialsOnco Targets Ther201581459146926109870
   PubMed Web of Science ®Google Scholar
• JohnsonTMOptimal management of elderly patients with myelomaConsult Pharm201429743443825203105
   PubMedGoogle Scholar
• HuttonBSalantiGCaldwellDMThe PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanationsAnn Intern Med20151621177778426030634
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• DurieBGHarousseauJLMiguelJSInternational uniform response criteria for multiple myelomaLeukemia20062091467147316855634
   PubMed Web of Science ®Google Scholar
• TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
   PubMed Web of Science ®Google Scholar
• ChaimaniAHigginsJPMavridisDSpyridonosPSalantiGGraphical tools for network meta-analysis in STATAPLoS One2013810e7665424098547
   PubMed Web of Science ®Google Scholar
• HigginsJPJacksonDBarrettJKLuGAdes AE4, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studiesRes Synth Methods2012329811026062084
   PubMed Web of Science ®Google Scholar
• RückerGNetwork meta-analysis, electrical networks and graph theoryRes Syn Methods201234312324
   PubMed Web of Science ®Google Scholar
• RückerGSchwarzerGKrahnUKönigJ [webpage on the Internet]netmeta: Network Meta-Analysis using Frequentist Methods. R package version 0.8-02015 Available from: http://cran.at.r-project.org/web/packages/netmeta/Accessed November 25, 2016
   Google Scholar
• RückerGSchwarzerGRanking treatments in frequentist network meta-analysis works without resampling methodsBMC Med Res Methodol2015155826227148
   PubMed Web of Science ®Google Scholar
• San-MiguelJBladéJShpilbergOPhase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myelomaBlood2014123264136414224833354
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSLiberatiAMOral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trialBlood200811283107311418505783
   PubMed Web of Science ®Google Scholar
• San MiguelJFSchlagRKhuagevaNKPersistent overall Survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJ Clin Oncol201331444845523233713
   PubMed Web of Science ®Google Scholar
• MateosMVOriolAMartínez-LópezJGEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?Blood2014124121887189325102853
   PubMed Web of Science ®Google Scholar
• MorganGJDaviesFEGregoryWMNCRI Haematological Oncology Study GroupCyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationBlood201111851231123821652683
   PubMed Web of Science ®Google Scholar
• BenboubkerLDimopoulosMADispenzieriAFIRST Trial TeamLenalidomide and dexamethasone in transplant-ineligible patients with myelomaN Engl J Med20143711090691725184863
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSPetrucciMTIntermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialBlood2004104103052305715265788
   PubMed Web of Science ®Google Scholar
• PalumboAHajekRDelforgeMMM-015 InvestigatorsContinuous lenalidomide treatment for newly diagnosed multiple myelomaN Engl J Med2012366191759176922571200
   PubMed Web of Science ®Google Scholar
• WaageAGimsingPFayersPNordic MyelomaStudy GroupMelphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myelomaBlood201011691405141220448107
   PubMed Web of Science ®Google Scholar
• HulinCFaconTRodonPEfficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trialJ Clin Oncol200927223664367019451428
   PubMed Web of Science ®Google Scholar
• BeksacMHaznedarRFiratli-TuglularTAddition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study GroupEur J Haematol2011861162220942865
   PubMed Web of Science ®Google Scholar
• WijermansPSchaafsmaMTermorshuizenFDutch-Belgium Cooperative Group HOVONPhase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 StudyJ Clin Oncol201028193160316620516439
   PubMed Web of Science ®Google Scholar
• FaconTMaryJYHulinCIntergroupe Francophone du MyélomeMelphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trialLancet200737095941209121817920916
   PubMed Web of Science ®Google Scholar
• LudwigHHajekRTóthováEThalidomide–dexamethasion compared with melphalan-prednisolone in elderly patients with multiple myelomaBlood2009113153435344218955563
   PubMed Web of Science ®Google Scholar
• NiesvizkyRFlinnIWRifkinRCommunity based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimensJ Clin Oncol201533333921392926056177
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSLaroccaABortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalJ Clin Oncol201432763464024449241
   PubMed Web of Science ®Google Scholar
• StewartAKJacobusSFonsecaRMelphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myelomaBlood2015126111294130126157076
   PubMed Web of Science ®Google Scholar
• ZweegmanSvan der HoltBMellqvistUHMelphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myelomaBlood201612791109111626802176
   PubMed Web of Science ®Google Scholar
• MagarottoVBringhenSOffidaniMTriplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaBlood201612791102110826729895
   PubMed Web of Science ®Google Scholar
• FayersPMPalumboAHulinCNordic Myeloma Study GroupItalian Multiple Myeloma NetworkTurkish Myeloma Study GroupHemato-Oncologie voor Volwassenen NederlandIntergroupe Francophone du MyélomeEuropean Myeloma NetworkThalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1,685 individual patient data from 6 randomized clinical trialsBlood201111851239124721670471
   PubMed Web of Science ®Google Scholar
• GrecoTEdefontiVBiondi-ZoccaiGA multilevel approach to network meta-analysis within a frequentist frameworkContemp Clin Trials201542515925804722
   PubMedGoogle Scholar
• ZhuGQShiKQHuangGQA network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitisOncotarget2015629267572676926378046
   PubMed Web of Science ®Google Scholar
• TMaiRZhouSZhongWTherapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trialsOncotarget2015629285022851226143635
   PubMedGoogle Scholar
• MhaskarRRedzepovicJWheatleyKBisphosphonates in multiple myeloma: a network meta-analysisCochrane Database Syst Rev20125CD003188
   PubMed Web of Science ®Google Scholar
• KrstevskaSBSotirovaTBalkanovTGenadieva-StavricSTreatment approach of nontransplant patients with multiple myelomaMater Sociomed201426534835125568637
   PubMedGoogle Scholar
• CejalvoMJde la RubiaJClinical treatment of newly diagnosed multiple myelomaExpert Rev Hematol20158559561126327587
   PubMed Web of Science ®Google Scholar